Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

The introduction in 1998 of imatinib mesylate (IM) revolutionized management of patients with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase inhibitors may prove superior to IM. Real-time quantitative polymerase chain reaction (RQ-PCR) provides an accurate measure of the...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Hughes, Timothy, Deininger, Michael, Hochhaus, Andreas, Branford, Susan, Radich, Jerald, Kaeda, Jaspal, Baccarani, Michele, Cortes, Jorge, Cross, Nicholas C. P., Druker, Brian J., Gabert, Jean, Grimwade, David, Hehlmann, Rüdiger, Kamel-Reid, Suzanne, Lipton, Jeffrey H., Longtine, Janina, Martinelli, Giovanni, Saglio, Giuseppe, Soverini, Simona, Stock, Wendy, Goldman, John M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: The American Society of Hematology 2006
Konular:
Review in Translational Hematology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895821/
https://ncbi.nlm.nih.gov/pubmed/16522812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-01-0092
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller